The Journal of Immunology, Vol 156, Issue 9 3166-3173, Copyright © 1996 by American Association of Immunologists

ARTICLES

Continuous administration of Il-13 to mice induces extramedullary hemopoiesis and monocytosis

YH Lai, JM Heslan, S Poppema, JF Elliot and TR Mosmann
Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Canada.

IL-13, a recently identified Th2 cytokine, shares some, but not all, IL- 4 functions, including inhibition of monocyte and macrophage activation, stimulation of human B cells, and induction of growth and differentiation of mouse bone marrow cells in vitro. We have now tested the in vivo effects of recombinant mouse IL-13 (rIL-13) from stably transfected, high expressing BW5147 thymoma cells. After purification by anion exchange chromatography, rIL-13 was administered in the peritoneal cavity of BALB/c mice via osmotic pump for 7 days. Spleens from the rIL-13-treated mice were significantly enlarged compared with control spleens due to increased cellularity. In particular, increased numbers of immature erythroblasts and megakaryocytes were observed in splenic sections after rIL-13 treatment. Spleen cells from rIL-13- treated mice showed greatly increased responsiveness in vitro to recombinant forms of mouse IL-3, mouse granulocyte-macrophage CSF, or human CSF-1 and, to a lesser extent, to mouse IL-4 or IL-13. Moreover, the rIL-13-treated mice also showed significant increases in CFU-E, CFU- C, and erythroid burst colonies in the spleen, further indicating the presence of increased numbers of hemopoietic precursors. Hematologic analyses indicated that rIL-13 treatment induced slight anemia and striking monocytosis. Finally, spleen cells from rIL-13-treated mice produced significantly more IL-6 upon LPS stimulation. Interestingly, the strong Th2 response induced by Nippostrongylus brasiliensis infection was also accompanied by an increase in hemopoietic precursor frequencies in the spleen. Collectively, these data indicate that exogenous rIL-13 induces extramedullary hemopoiesis in mice and suggest that endogenous IL-13 may contribute to replenishment of effector cells during strong Th2 responses.

This article has been cited by other articles:

				D. Chiavolini, J. Alroy, C. A. King, P. Jorth, S. Weir, G. Madico, J. R. Murphy, and L. M. Wetzler Identification of Immunologic and Pathologic Parameters of Death versus Survival in Respiratory Tularemia Infect. Immun., February 1, 2008; 76(2): 486 - 496. [Abstract] [Full Text] [PDF]

				S. M. Shin, Y. H. Kim, B. K. Choi, P. M. Kwon, H.-W. Lee, and B. S. Kwon 4-1BB triggers IL-13 production from T cells to limit the polarized, Th1-mediated inflammation J. Leukoc. Biol., June 1, 2007; 81(6): 1455 - 1465. [Abstract] [Full Text] [PDF]

				K.-R. Koh, M. Janz, M. Y. Mapara, B. Lemke, D. Stirling, B. Dorken, M. Zenke, and S. Lentzsch Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis Blood, May 15, 2005; 105(10): 3833 - 3840. [Abstract] [Full Text] [PDF]

				J. P. Monteiro, A. Benjamin, E. S. Costa, M. A. Barcinski, and A. Bonomo Normal hematopoiesis is maintained by activated bone marrow CD4+ T cells Blood, February 15, 2005; 105(4): 1484 - 1491. [Abstract] [Full Text] [PDF]

				M. Terme, E. Tomasello, K. Maruyama, F. Crepineau, N. Chaput, C. Flament, J.-P. Marolleau, E. Angevin, E. F. Wagner, B. Salomon, et al. IL-4 Confers NK Stimulatory Capacity to Murine Dendritic Cells: A Signaling Pathway Involving KARAP/DAP12-Triggering Receptor Expressed on Myeloid Cell 2 Molecules J. Immunol., May 15, 2004; 172(10): 5957 - 5966. [Abstract] [Full Text] [PDF]

				N. Wood, M. J. Whitters, B. A. Jacobson, J. Witek, J. P. Sypek, M. Kasaian, M. J. Eppihimer, M. Unger, T. Tanaka, S. J. Goldman, et al. Enhanced Interleukin (IL)-13 Responses in Mice Lacking IL-13 Receptor {alpha} 2 J. Exp. Med., March 17, 2003; 197(6): 703 - 709. [Abstract] [Full Text] [PDF]

				N. de Geest, E. Bonten, L. Mann, J. de Sousa-Hitzler, C. Hahn, and A. d'Azzo Systemic and neurologic abnormalities distinguish the lysosomal disorders sialidosis and galactosialidosis in mice Hum. Mol. Genet., June 1, 2002; 11(12): 1455 - 1464. [Abstract] [Full Text] [PDF]

				H. Tagaya, T. Kunisada, H. Yamazaki, T. Yamane, T. Tokuhisa, E. F. Wagner, T. Sudo, L. D. Shultz, and S.-I. Hayashi Intramedullary and extramedullary B lymphopoiesis in osteopetrotic mice Blood, June 1, 2000; 95(11): 3363 - 3370. [Abstract] [Full Text] [PDF]

				J. Poudrier, P. Graber, S. Herren, D. Gretener, G. Elson, C. Berney, J.-F. Gauchat, and M. H. Kosco-Vilbois A Soluble Form of IL-13 Receptor {alpha}1 Promotes IgG2a and IgG2b Production by Murine Germinal Center B Cells J. Immunol., August 1, 1999; 163(3): 1153 - 1161. [Abstract] [Full Text] [PDF]

				L. Li, Y. Xia, A. Nguyen, Y. H. Lai, L. Feng, T. R. Mosmann, and D. Lo Effects of Th2 Cytokines on Chemokine Expression in the Lung: IL-13 Potently Induces Eotaxin Expression by Airway Epithelial Cells J. Immunol., March 1, 1999; 162(5): 2477 - 2487. [Abstract] [Full Text] [PDF]

				Y. H. Lai and T. R. Mosmann Mouse IL-13 Enhances Antibody Production In Vivo and Acts Directly on B Cells In Vitro to Increase Survival and Hence Antibody Production J. Immunol., January 1, 1999; 162(1): 78 - 87. [Abstract] [Full Text] [PDF]

				F. G Roberge, M. D de Smet, J. Benichou, M. F Kriete, J. Raber, and J. Hakimi Treatment of uveitis with recombinant human interleukin-13 Br. J. Ophthalmol., October 1, 1998; 82(10): 1195 - 1198. [Abstract] [Full Text]

				P. J. Murray, R. A. Young, and G. Q. Daley Hematopoietic Remodeling in Interferon-gamma -Deficient Mice Infected With Mycobacteria Blood, April 15, 1998; 91(8): 2914 - 2924. [Abstract] [Full Text] [PDF]

				A. J. Bancroft, A. N. J. McKenzie, and R. K. Grencis A Critical Role for IL-13 in Resistance to Intestinal Nematode Infection J. Immunol., April 1, 1998; 160(7): 3453 - 3461. [Abstract] [Full Text] [PDF]